- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00022698
Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
A Phase II Study of Oral Xeloda (Capecitabine) in Combination With Intravenous Irinotecan for Patients With Locally Advanced and/or Metastatic Colorectal Cancer
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
OBJECTIVES:
Primary:
- Determine the overall objective response rate in patients with locally advanced, locally recurrent, or metastatic colorectal cancer treated with capecitabine and irinotecan.
Secondary:
- Determine the time to treatment failure, time to overall response, duration of overall response, duration of overall complete response, and time to progression in patients treated with this regimen.
- Determine the 1-year survival and overall survival of patients treated with this regimen.
- Determine the toxicity and safety profile of this regimen in these patients.
- Determine the feasibility of predicting responses to this regimen by the molecular profile of tumor tissue in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive oral capecitabine twice daily on days 2-15 and irinotecan IV over 90 minutes on days 1 and 8. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients maintaining a response or stable disease after 12 courses may continue treatment at the discretion of the investigator.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 65 patients will be accrued for this study within 9 months.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35294-3300
- University of Alabama at Birmingham Comprehensive Cancer Center
-
-
California
-
Loma Linda, California, Stany Zjednoczone, 92354
- Loma Linda University Cancer Institute at Loma Linda University Medical Center
-
-
Connecticut
-
Norwich, Connecticut, Stany Zjednoczone, 06360
- Eastern Connecticut Hematology and Oncology Associates
-
-
District of Columbia
-
Washington, District of Columbia, Stany Zjednoczone, 20007
- Lombardi Cancer Center at Georgetown University Medical Center
-
Washington, District of Columbia, Stany Zjednoczone, 20037
- George Washington University Medical Center
-
-
Florida
-
Jacksonville, Florida, Stany Zjednoczone, 32209
- University of Florida Health Science Center - Jacksonville
-
-
Kentucky
-
Lexington, Kentucky, Stany Zjednoczone, 40536-0084
- Markey Cancer Center at University of Kentucky Chandler Medical Center
-
-
Missouri
-
Saint Louis, Missouri, Stany Zjednoczone, 63110-0250
- St. Louis University Hospital Cancer Center
-
-
New York
-
Bronx, New York, Stany Zjednoczone, 10451
- Lincoln Medical and Mental Health Center
-
Brooklyn, New York, Stany Zjednoczone, 11235
- HemOnCare, P.C.
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19107-5541
- Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone, 29403
- Charleston Hematology-Oncology, P.A.
-
-
Virginia
-
Charlottesville, Virginia, Stany Zjednoczone, 22908
- Cancer Center at the University of Virginia
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98104
- Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
-
Spokane, Washington, Stany Zjednoczone, 99202
- Rockwood Clinic P.S.
-
-
West Virginia
-
Morgantown, West Virginia, Stany Zjednoczone, 26506-9300
- West Virginia University Hospitals
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
DISEASE CHARACTERISTICS:
- Histologically confirmed locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma
At least 1 measurable lesion
- At least 10 mm by spiral CT scan
- At least 20 mm by conventional techniques
- Bone metastases, ascites, or pleural effusions are not considered measurable disease
- No evidence of CNS metastases
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Karnofsky 80-100%
Life expectancy:
- Not specified
Hematopoietic:
- Neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Bilirubin no greater than 1.25 times upper limit of normal (ULN)
- ALT and AST no greater than 2.5 times ULN (5 times ULN if liver metastases present)
- Alkaline phosphatase no greater than 2.5 times ULN (5 times ULN if liver metastases present or 10 times ULN if bone metastases present)
- No known Gilbert's disease
Renal:
- Creatinine no greater than 1.5 times ULN
- Creatinine clearance at least 50 mL/min
Cardiovascular:
- No clinically significant cardiac disease
- No congestive heart failure
- No symptomatic coronary artery disease
- No cardiac arrhythmias uncontrolled with medication
- No myocardial infarction within the past 12 months
Gastrointestinal:
- Able to swallow tablets
- No lack of physical integrity of the upper gastrointestinal tract
- No malabsorption syndrome
Other:
- No prior unanticipated severe reaction to fluoropyrimidine therapy
- No hypersensitivity to fluorouracil
- No history of uncontrolled seizures or CNS disorders
- No psychological illness or condition that would preclude study entry
- No other malignancy within the past 5 years except curatively treated basal cell skin cancer or carcinoma in situ of the cervix
- No serious infection
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- At least 12 months since prior neoadjuvant or adjuvant, active or passive immunotherapy
- No concurrent active or passive immunotherapy (e.g., 17-1A antibody) for colon cancer
- No concurrent prophylactic hematopoietic growth factors
Chemotherapy:
- At least 12 months since prior neoadjuvant or adjuvant cytotoxic chemotherapy
- No prior chemotherapy for metastatic colorectal cancer
- No prior therapy with irinotecan or capecitabine
- No other concurrent cytotoxic agents
Endocrine therapy:
- Not specified
Radiotherapy:
- At least 4 weeks since prior radiotherapy
- No prior radiotherapy to measurable lesion (newly arising lesions in a previously irradiated area allowed)
- No concurrent radiotherapy
Surgery:
- At least 4 weeks since prior major surgery and recovered
- No prior organ allograft
Other:
- At least 4 weeks since prior participation in an investigational drug study
- No other concurrent investigational drugs
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Cohort 1,Initial Regimen:(Capecitabine + Irinotecan )
Participants will receive capecitabine (Xeloda) 1000 mg/m^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 125 mg/m^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks.
A total of 12 cycles of treatment will be administered.
At the discretion of the investigator, participants who are responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase.
Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).
|
|
Eksperymentalny: Cohort 2,Amended Regimen:(Capecitabine + Irinotecan)
Participants will receive capecitabine 900 mg/m^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 100 mg/m^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks.
A total of 12 cycles of treatment will be administered.
At the discretion of the investigator, participants who will be responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase.
Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Tumor Response Rate Based on Tumor Measurement as Per Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST 1.0)
Ramy czasowe: Approximately 43 Months
|
Objective Response Rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST 1.0).
CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level.
PR is defined as a greater than or equal to (>/=) 30% decrease in the sum of the longest diameter (LD) of the target lesions, taking as reference the baseline sum of LD.
Participants who did not have a post-baseline tumor measurement were considered non-responders in the assessment of ORR.
|
Approximately 43 Months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Time to Disease Progression
Ramy czasowe: Approximately 43 Months
|
Time to disease progression was assessed as the time from start of treatment to the time the participant was first recorded as having disease progression or died due to causes other than disease progression.
If a participant never progressed while being followed, he/she was censored at the date of the last tumor assessment or the date of the last dose if no post-baseline tumor measurement was available.
|
Approximately 43 Months
|
Time to Treatment Failure
Ramy czasowe: Approximately 43 Months
|
Time to treatment failure was assessed as the time from start of treatment to the time the participant was withdrawn due to any of the reasons such as adverse events, progressive disease, insufficient therapeutic response, death, failure to return, or refused treatment, did not cooperate or withdrew consent.
|
Approximately 43 Months
|
Percentage of Participants With One-year Survival
Ramy czasowe: Up to Month 12
|
Survival was measured as the time from start of treatment to the date of death or till one year whichever occurred first.
|
Up to Month 12
|
Overall Survival
Ramy czasowe: Approximately 43 Months
|
Overall Survival is defined as the time from start of treatment to the date of death.
Participants who did not die were censored at the last date the participant was known to be alive.
|
Approximately 43 Months
|
Time To Objective Response
Ramy czasowe: Approximately 43 Months
|
The time to objective response is defined as the time from start of treatment to the date of first objective response.
Participants who never responded during study were censored at the last tumor assessment or the date of last dose, whichever was later, or at the date of death if occurring prior to response.
|
Approximately 43 Months
|
Duration of Overall Response
Ramy czasowe: Approximately 43 Months
|
Duration of overall response was assessed from the time that measurement criteria were first met for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease was documented.
It was analyzed for responders only.
Participants without observed progressive disease after an objective response were censored at the date of the last tumor assessment.
|
Approximately 43 Months
|
Duration of Overall Complete Response
Ramy czasowe: Approximately 43 Months
|
The duration of overall complete response was assessed from the time that measurement criteria were met for complete response until the first date that recurrent or progressive disease was objectively documented.
Participants without observed progressive disease after an objective complete response were censored at the date of the last tumor assessment.
|
Approximately 43 Months
|
Number of Participants With Any Adverse Events, Serious Adverse Events and Deaths
Ramy czasowe: Approximately 43 Months
|
An adverse event (AEs) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.
An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
Preexisting conditions which worsen during a study are also considered as adverse events.
A serious adverse event is defined as any event which was fatal (resulted in death), life-threatening (with immediate risk of death), resulted in a new or prolongation of a current hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, considered medically significant by the investigator, required intervention to prevent one or more of the outcomes listed above.
|
Approximately 43 Months
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Publikacje ogólne
- Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006 Sep 1;24(25):4069-77. doi: 10.1200/JCO.2005.05.2084.
- Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby Układu Pokarmowego
- Nowotwory
- Nowotwory według lokalizacji
- Nowotwory przewodu pokarmowego
- Nowotwory Układu Pokarmowego
- Choroby przewodu pokarmowego
- Choroby okrężnicy
- Choroby jelit
- Nowotwory jelit
- Choroby odbytu
- Nowotwory jelita grubego
- Molekularne mechanizmy działania farmakologicznego
- Inhibitory enzymów
- Antymetabolity, przeciwnowotworowe
- Antymetabolity
- Środki przeciwnowotworowe
- Inhibitory topoizomerazy
- Inhibitory topoizomerazy I
- Kapecytabina
- Irynotekan
Inne numery identyfikacyjne badania
- ML16323
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Rak jelita grubego
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Aktywny, nie rekrutującyGruczolakorak gruczołu krokowego III stopnia AJCC v7 | Gruczolakorak gruczołu krokowego II stopnia AJCC v7 | Stopień I gruczolakoraka gruczołu krokowego American Joint Committee on Cancer (AJCC) v7Stany Zjednoczone
-
Emory UniversityNational Cancer Institute (NCI)WycofanePrognostyczny rak piersi IV stopnia AJCC v8 | Przerzutowy nowotwór złośliwy w mózgu | Przerzutowy rak piersi | Anatomiczny IV stopień raka piersi American Joint Committee on Cancer (AJCC) v8
-
Jonsson Comprehensive Cancer CenterZakończonyRak prostaty oporny na kastrację | Przerzutowy rak prostaty | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterEli Lilly and Company; Genentech, Inc.RekrutacyjnyNiedrobnokomórkowy rak płuc z przerzutami | Oporny na leczenie niedrobnokomórkowy rak płuc | Rak płuca w stadium IV American Joint Committee on Cancer (AJCC) v8 | Rak płuc w stadium IVA AJCC v8 | Rak płuc w stadium IVB AJCC v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterZakończonyBiochemicznie nawracający rak prostaty | Przerzutowy rak prostaty | Nowotwór złośliwy z przerzutami w kości | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
NRG OncologyNational Cancer Institute (NCI)Aktywny, nie rekrutującyAnatomiczny rak piersi IV stadium AJCC v8 | Prognostyczny rak piersi IV stopnia AJCC v8 | Nowotwór złośliwy z przerzutami w kości | Przerzutowy nowotwór złośliwy w węzłach chłonnych | Przerzutowy nowotwór złośliwy w wątrobie | Przerzutowy rak piersi | Przerzutowy nowotwór złośliwy w płucach | Nowotwór... i inne warunkiStany Zjednoczone, Kanada, Arabia Saudyjska, Republika Korei
-
Jonsson Comprehensive Cancer CenterRekrutacyjnyRak prostaty oporny na kastrację | Przerzutowy rak prostaty | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
National Cancer Institute (NCI)ZakończonyOporny na leczenie złośliwy nowotwór lity | Nawracający złośliwy nowotwór lity | Przerzutowy złośliwy nowotwór lity | Nieoperacyjny lity nowotwór | Nawracający rak drobnokomórkowy płuca | Stopień IIIA Rak drobnokomórkowy płuca AJCC v7 | Etap IIIB Rak drobnokomórkowy płuca AJCC v7 | Rak drobnokomórkowy... i inne warunkiStany Zjednoczone
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWycofanePrzerzutowy rak nerkowokomórkowy | Rak nerkowokomórkowy IV stopnia AJCC v8 | Rak brodawkowaty nerki | Zbieranie raka przewodów | Nieoperacyjny rak nerki | Dziedziczna leiomyomatoza i rak nerkowokomórkowy | Jasnokomórkowy brodawkowaty nowotwór nerki | Dziedziczny rak brodawkowaty nerki | Niesklasyfikowany... i inne warunkiStany Zjednoczone
-
Jonsson Comprehensive Cancer CenterAstraZenecaZakończonyRak płaskonabłonkowy jamy ustnej i gardła | Stopień kliniczny III zależny od HPV (p16-dodatni) rak jamy ustnej i gardła AJCC v8 | Stopień kliniczny II, w którym pośredniczy HPV (p16-dodatni) rak jamy ustnej i gardła AJCC v8 | Patologiczny etap I, w którym pośredniczy HPV (p16-dodatni) rak jamy... i inne warunkiStany Zjednoczone
Badania kliniczne na Kapecytabina
-
AstraZenecaSWOG Clinical Trials Partnerships; Daiichi SankyoRekrutacyjnyRak piersiStany Zjednoczone, Chiny, Dania, Zjednoczone Królestwo, Republika Korei, Kanada, Niemcy, Włochy, Belgia, Hiszpania, Japonia, Francja, Tajwan, Grecja, Brazylia, Szwecja, Portoryko
-
Institute of Oncology LjubljanaNieznany
-
AstraZenecaDaiichi SankyoRekrutacyjnyRak piersiHiszpania, Chiny, Stany Zjednoczone, Włochy, Zjednoczone Królestwo, Republika Korei, Belgia, Francja, Niemcy, Japonia, Wietnam, Kanada, Brazylia, Indie, Malezja, Tajwan, Australia, Austria, Tajlandia, Indyk, Hongkong, Polska, Szwajc... i więcej
-
Assistance Publique - Hôpitaux de ParisAktywny, nie rekrutującyRak dróg żółciowychFrancja
-
University of Erlangen-Nürnberg Medical SchoolRekrutacyjny
-
Hebei Medical UniversityNieznanyRak żołądka | Przerzuty do wątrobyChiny